In terms of health, research and biomedical development, the expertise of Cuban practitioners is recognized worldwide. This is particularly the case for the treatment of diabetic feet, which often have to be amputated due to a lack of healing. Professor Jorge Berlanga has found a drug capable of reducing the number of such complications: Heberprot-P. This product, already authorized in the United States, is not yet authorized in France.
The seventh International Medical Congress on Diabetic Foot Wounds and Healing was held in Cuba, from September 1 to 4, 2024.
A delegation from Guadeloupe was present on site: Doctor Martin Mukisi, specialist in orthopedics and traumatology and Doctor Henri Joseph, specialist in pharmacognosy, in particular. With the 250 other experts, from 25 countries, they discussed a miraculous product, invented by the Cuban researcher Professor Jorge Berlanga, aimed at reducing the number of amputations in diabetic patients.
In Guadeloupe, 300 lower limb amputations are performed each year due to wounds that do not heal, including those on diabetic feet. However, 12% of the local population, or approximately 40,000 people, suffer from diabetes; these patients are therefore at risk of losing one or both lower limbs in the event of complications.
Hence the interest in the drug discovered by Cuba; this product, Heberprot-P, has proven itself on 450,000 people in the 25 countries where it has already been used.
In Colombia, for example, out of 469 patients treated, only three had to be amputated.
During his visit to Guadeloupe last May, the treatment inventor announced that the United States had validated clinical trials on their territory.
In the archipelago, he was also able to appreciate the expertise of telemedicine in wounds and healing; a field mastered by Dr. Martin Mukisi, who works at the Pitat medical-social center in Basse-Terre.
He also has an interest in the valorization of natural substances in the field of healing; a subject dear to Dr. Henri Joseph, developed within the Phytobòkaz laboratory.
In return, Prof. Berlanga invited these two experts to participate in this week’s Congress in Cuba.
One question remains: when will the French Ministry of Health approve the use of Heberprot-P in hospitals in the Antilles and Guyana, where complications related to diabetes are frequent?
As a reminder, the seventh edition of the International Congress on Wound Healing in the Antilles (CICA) was organized before this major Cuban event, on June 20 and 21, 2024, in Gosier, Guadeloupe. Already, hundreds of participants had rushed to discuss this subject, which concerns a large number of diabetic patients in our latitudes.
ALSO READ: A Congress to explore wound healing in depth – 06/22/2024.
